Patents Assigned to BIOASIS TECHNOLOGIES INC.
-
Patent number: 11643454Abstract: Provided are p97 (melanotransferrin)-trastuzumab fusion proteins and related methods of use thereof, for instance, to facilitate delivery of trastuzumab across the blood-brain barrier (BBB) and/or improve tissue penetration of the antibody in CNS and peripheral tissues, and thereby treat and/or diagnose HER2-positive cancers, including those of the central nervous system (CNS).Type: GrantFiled: February 10, 2019Date of Patent: May 9, 2023Assignee: BIOASIS TECHNOLOGIES, INC.Inventors: Timothy Z. Vitalis, Reinhard Gabathuler
-
Publication number: 20220162336Abstract: Disclosed are therapeutic payloads comprising p97 fragments coupled with active agents having blood-brain barrier (BBB) transport activity, including variants and combinations thereof, to facilitate delivery of therapeutic or diagnostic agents across the BBB. The therapeutic payloads can be effective in the treatment of conditions which involve the lymphatic system of the subject, and may also present a disease state in the brain of the subject. Methods of treating diseases involving the lymphatic system and pharmaceutical compositions are also disclosed.Type: ApplicationFiled: July 19, 2019Publication date: May 26, 2022Applicant: Bioasis Technologies, Inc.Inventors: Mei Mei Tian, Mark Day
-
Publication number: 20220048992Abstract: Provided are compositions and methods related to the co-administration of an immunoglobulin Fc region-containing polypeptide and a central nervous system (CNS)-targeted antibody or Fc-fusion polypeptide conjugate, to improve pharmacokinetics and/or delivery of the conjugate across the blood-brain barrier (BBB). Also provided are methods of treatment of indications and diseases of the CNS and indications and diseases with a CNS component.Type: ApplicationFiled: August 13, 2021Publication date: February 17, 2022Applicant: Bioasis Technologies, Inc.Inventors: Reinhard Gabathuler, Mei Mei Tian
-
Publication number: 20210393787Abstract: Disclosed are therapeutic payloads comprising p97 fragments coupled with active agents having blood-brain barrier (BBB) transport activity, including variants and combinations thereof, to facilitate delivery of therapeutic or diagnostic agents across the BBB. The therapeutic payloads can be effective in the treatment of frontotemportal dementia (FTD). Methods of treating frontotemporal dementia (FTD) and pharmaceutical compositions are also disclosed.Type: ApplicationFiled: June 15, 2021Publication date: December 23, 2021Applicant: Bioasis Technologies, Inc.Inventors: Deborah Rathjen, Mei Mei Tian
-
Publication number: 20210388330Abstract: Provided are substantially dephosphorylated forms of lysosomal storage disease (LSD) proteins, including dephosphorylated forms of iduronate-2-sulfatase (IDS, or 12D) and iduronidase (IDU), having increased ability to traverse or penetrate the blood brain barrier (BBB) relative to phosphorylated forms of the protein, and p97 conjugates thereof. Also provided are compositions comprising such dephosphorylated LSD proteins and p97 conjugates, and methods of use thereof, for instance, to treat any one or more lysosomal storage diseases, such as Hunter Syndrome (or MPS Type II).Type: ApplicationFiled: June 11, 2021Publication date: December 16, 2021Applicant: Bioasis Technologies, Inc.Inventors: Timothy Vitalis, Reinhard Gabathuler
-
Patent number: 11124781Abstract: Provided are fusion proteins between p97 (melanotransferrin) and iduronate-2-sulfatase (IDS), and related compositions and methods of use thereof, for instance, to facilitate delivery of IDS across the blood-brain barrier (BBB) and/or improve its tissue penetration in CNS and/or peripheral tissues, and thereby treat and/or diagnose Hunter Syndrome (Mucopolysaccharidosis type II; MPS II) and related lysosomal storage disorders, including those having a central nervous system (CNS) component.Type: GrantFiled: June 22, 2019Date of Patent: September 21, 2021Assignee: Bioasis Technologies, Inc.Inventors: Timothy Z. Vitalis, Reinhard Gabathuler
-
Patent number: 11034943Abstract: Provided are substantially dephosphorylated forms of lysosomal storage disease (LSD) proteins, including dephosphorylated forms of iduronate-2-sulfatase (IDS, or I2D) and iduronidase (IDU), having increased ability to traverse or penetrate the blood brain barrier (BBB) relative to phosphorylated forms of the protein, and p97 conjugates thereof. Also provided are compositions comprising such dephosphorylated LSD proteins and p97 conjugates, and methods of use thereof, for instance, to treat any one or more lysosomal storage diseases, such as Hunter Syndrome (or MPS Type II).Type: GrantFiled: April 2, 2018Date of Patent: June 15, 2021Assignee: biOasis Technologies, Inc.Inventors: Timothy Z. Vitalis, Reinhard Gabathuler
-
Publication number: 20210113703Abstract: Disclosed are therapeutic payloads comprising p97 fragments coupled with active agents having blood-brain barrier (BBB) transport activity, including variants and combinations thereof, to facilitate delivery of therapeutic or diagnostic agents across the BBB. The therapeutic payloads can be effective in the treatment of Gaucher disease. Methods of treating Gaucher disease and pharmaceutical compositions are also disclosed.Type: ApplicationFiled: May 18, 2019Publication date: April 22, 2021Applicant: Bioasis Technologies Inc.Inventors: Mei Mei Tian, Mark Day
-
Publication number: 20210046149Abstract: Disclosed are therapeutic payloads comprising p97 fragments coupled with active agents having blood-brain barrier (BBB) transport activity, including variants and combinations thereof, to facilitate delivery of therapeutic or diagnostic agents across the BBB. The therapeutic payloads have dual functionality that may permit treatment of diseases in a subject other than diseases that present in the brain, e.g., solid tumors in the body. Methods of treating various diseases and pharmaceutical compositions are also disclosed.Type: ApplicationFiled: March 21, 2019Publication date: February 18, 2021Applicant: Bioasis Technologies, Inc.Inventor: Mei Mei Tian
-
Publication number: 20200376092Abstract: Provided are fragments of human p97 (melanotransferrin) polypeptides having blood-brain barrier (BBB) transport activity, including variants and combinations thereof, conjugates comprising the p97 fragments, and related methods of use thereof, for instance, to facilitate the delivery of therapeutic or diagnostic agents across the BBB and into the central nervous system.Type: ApplicationFiled: August 13, 2020Publication date: December 3, 2020Applicant: Bioasis Technologies, Inc.Inventors: Timothy Z. Vitalis, Reinhard Gabathuler
-
Patent number: 10772939Abstract: Provided are fragments of human p97 (melanotransferrin) polypeptides having blood-brain barrier (BBB) transport activity, including variants and combinations thereof, conjugates comprising the p97 fragments, and related methods of use thereof, for instance, to facilitate delivery of therapeutic or diagnostic agents across the BBB.Type: GrantFiled: May 8, 2018Date of Patent: September 15, 2020Assignee: Bioasis Technologies, Inc.Inventors: Timothy Z. Vitalis, Reinhard Gabathuler
-
Patent number: 10392605Abstract: Provided are fusion proteins between p97 (melanotransferrin) and iduronate-2-sulfatase (IDS), and related compositions and methods of use thereof, for instance, to facilitate delivery of IDS across the blood-brain barrier (BBB) and/or improve its tissue penetration in CNS and/or peripheral tissues, and thereby treat and/or diagnose Hunter Syndrome (Mucopolysaccharidosis type II; MPS II) and related lysosomal storage disorders, including those having a central nervous system (CNS) component.Type: GrantFiled: February 12, 2015Date of Patent: August 27, 2019Assignee: Bioasis Technologies Inc.Inventors: Timothy Z. Vitalis, Reinhard Gabathuler
-
Patent number: 10058619Abstract: Provided are conjugates between p97 (melanotransferrin) and polynucleotides such as small interfering RNA (siRNA) molecules, and related compositions and methods of use thereof, for instance, to facilitate delivery of polynucleotides such as siRNA molecules across the blood-brain barrier (BBB) and/or improve their tissue penetration in CNS and/or peripheral tissues, and thereby treat and/or diagnose various diseases, including those having a central nervous system (CNS) component.Type: GrantFiled: May 1, 2015Date of Patent: August 28, 2018Assignee: Bioasis Technologies, Inc.Inventors: Wilfred Jefferies, Reinhard Gabathuler
-
Patent number: 9993530Abstract: Provided are fragments of human p97 (melanotransferrin) polypeptides having blood-brain barrier (BBB) transport activity, including variants and combinations thereof, conjugates comprising the p97 fragments, and related methods of use thereof, for instance, to facilitate delivery of therapeutic or diagnostic agents across the BBB.Type: GrantFiled: May 12, 2016Date of Patent: June 12, 2018Assignee: Bioasis Technologies, Inc.Inventors: Timothy Z. Vitalis, Reinhard Gabathuler
-
Patent number: 9932565Abstract: Provided are substantially dephosphorylated forms of lysosomal storage disease (LSD) proteins, including dephosphorylated forms of iduronate-2-sulfatase (IDS, or I2D) and iduronidase (IDU), having increased ability to traverse or penetrate the blood brain barrier (BBB) relative to phosphorylated forms of the protein, and p97 conjugates thereof. Also provided are compositions comprising such dephosphorylated LSD proteins and p97 conjugates, and methods of use thereof, for instance, to treat any one or more lysosomal storage diseases, such as Hunter Syndrome (or MPS Type II).Type: GrantFiled: July 31, 2013Date of Patent: April 3, 2018Assignee: biOasis Technologies, Inc.Inventors: Timothy Z. Vitalis, Reinhard Gabathuler
-
Patent number: 9850472Abstract: The present invention provides p97-antibody conjugates and related compositions and methods, which may be used in any of a variety of therapeutic methods, including methods for the treatment of cancers such as Her2/neu-expressing and Her1/EGFR-expressing cancers.Type: GrantFiled: August 27, 2015Date of Patent: December 26, 2017Assignee: BIOASIS TECHNOLOGIES, INC.Inventors: Timothy Z. Vitalis, Reinhard Gabathuler
-
Patent number: 9364567Abstract: Provided are fragments of human p97 (melanotransferrin) polypeptides having blood-brain barrier (BBB) transport activity, including variants and combinations thereof, conjugates comprising the p97 fragments, and related methods of use thereof, for instance, to facilitate delivery of therapeutic or diagnostic agents across the BBB.Type: GrantFiled: March 13, 2014Date of Patent: June 14, 2016Assignee: biOasis Technologies, Inc.Inventors: Timothy Z. Vitalis, Reinhard Gabathuler
-
Publication number: 20160053237Abstract: The present invention provides p97-antibody conjugates and related compositions and methods, which may be used in any of a variety of therapeutic methods, including methods for the treatment of cancers such as Her2/neu-expressing and Her1/EGFR-expressing cancers.Type: ApplicationFiled: August 27, 2015Publication date: February 25, 2016Applicant: BIOASIS TECHNOLOGIES, INC.Inventors: Wilfred Jefferies, Timothy Z. Vitalis, Reinhard Gabathuler
-
Patent number: 9161992Abstract: The present invention is related to fragments of human melanotransferrin (p97). In particular, this invention relates to treatment of diseases through the introduction of the melanotransferrin fragment conjugated to a therapeutic or diagnostic agent to a subject.Type: GrantFiled: March 26, 2014Date of Patent: October 20, 2015Assignee: biOasis Technologies, Inc.Inventors: Wilfred Jefferies, Mei Mei Tian, Timothy Vitalis
-
Patent number: 9150846Abstract: The present invention provides p97-antibody conjugates and related compositions and methods, which may be used in any of a variety of therapeutic methods, including methods for the treatment of cancers such as Her2/neu-expressing and Her1/EGFR-expressing cancers.Type: GrantFiled: July 5, 2012Date of Patent: October 6, 2015Assignee: biOasis Technologies, Inc.Inventors: Wilfred Jefferies, Timothy Z. Vitalis, Reinhard Gabathuler